Why OSTX rose 23.1% on Oct 6 2026: phase 2b survival data
OSTX+23.1%on Tue Oct 6 2026
OS Therapies Incorporated was up 23.1% on the day at $1.97, ranked #2 on 272× its usual five-minute volume, when TapeRank recorded this spike at 09:11 ET during the pre-market session.
THE DAY ON THE LIST · 1 EVENT
- 09:11 ETMOVER · PRE-MARKET
$1.97 · ▲ 23.1% ON THE DAY · 272× 5M RVOL · RANK #2
JUSTIFIEDCONFIDENCE5/5OSTX is up 15.0% pre-market, with accelerating volume, after reporting a statistically significant three-year overall-survival benefit in its Phase 2b osteosarcoma trial. The 72.7% survival rate versus 45.8% historical control and p=0.0006 are material clinical results that support a substantial move, though they do not establish approval or commercialization.
WHYA 15% move is proportionate to a statistically significant Phase 2b survival result with a 26.9-point benefit, rather than an unquantified corporate announcement.ANALYZED 09:02 ET · 9 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 09:11 ET
LAST1.97DAY▲ 23.1%5 MIN▲ 7.65%5M RVOL272×5M $VOL$573KFLOAT*4.6MRANK#2SESSIONPRE-MARKETVWAP1.79HOD1.92LOD1.64OR HIGH—OR LOW—PREV CLOSE1.60PM HIGH1.92PM LOW1.64GAP▲ 18.75% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $1.71, +6.9% on the previous close of $1.60
- 11:05 ETRegular-session high, $1.74
- 15:46 ETRegular-session low, $1.47
- 15:59 ETLast trade of the regular session, $1.48, -7.5% on the previous close of $1.60
- Volume: 3.5M shares in regular hours, 2.5M before the open
OSTX began with a premarket surge, reaching $1.97 at 09:11 ET after TapeRank’s read tied the move to OS Therapies reporting a statistically significant three-year overall-survival benefit in its Phase 2b osteosarcoma trial. It opened at $1.71, briefly rose to $1.74 by 11:05 ET, then reversed lower through the afternoon to a $1.47 low at 15:46 ET before ending at $1.48, below the previous close of $1.60. No halts were recorded, and TapeRank found the Phase 2b survival data, rather than the prior-day SEC 8-K, explained the move.
WRITTEN THU OCT 15 2026 18:02 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 08:40 ETOS Therapies Announces Statistically Significant Final 3-Yr Overall Survival Benefit For OST-HER2-Treated Patients In Phase 2b Trial In Pulmonary Metastatic Osteosarcoma Compared With Combined Published Historical ControlBenzinga
- MON 16:37 ET8-K — Entry into a Material Definitive Agreement; Departure or Election of Directors or Officers; Other Events; Financial Statements and ExhibitsSEC 8-K
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list